Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YIC therapeutic hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Beijing Institute of Biological Products
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
YIC therapeutic hepatitis B vaccine is an antigen-antibody immunocomplex (AIC) therapeutic vaccine candidate developed for the treatment of chronic hepatitis B (CHB). It consists of yeast-derived hepatitis B surface antigen (HBsAg) complexed with human hepatitis B immunoglobulin (HBIG) in a specific ratio, typically formulated with an aluminum hydroxide adjuvant. The vaccine is designed to overcome the immune tolerance observed in CHB patients by facilitating the uptake of HBsAg by dendritic cells through Fc gamma receptor-mediated endocytosis. This enhanced antigen presentation is intended to stimulate potent HBV-specific T-cell responses, particularly CD8+ cytotoxic T lymphocytes, to clear virus-infected hepatocytes. Developed by researchers at Fudan University in collaboration with Shenzhen Kangtai Biological Products and Beijing Ditan Hospital, YIC has been evaluated in multiple clinical trials, including a large-scale Phase 3 study in China targeting HBeAg-positive treatment-naïve adults.
- Other names
- HBsAg-HBIG immunocomplex vaccineYeast-derived Immunocomplex vaccinetherapeutic hepatitis B vaccine (YIC)AIC-HBV
02
Targets
HBsAg (Hepatitis B surface antigen)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on YIC therapeutic hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YIC therapeutic hepatitis B vaccine.